Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07804849
PHASE2/PHASE3

Oral Verapamil Among Newly Diagnosed Children and Adolescents With Type 1 Diabetes

Sponsor: Ain Shams University

View on ClinicalTrials.gov

Summary

Type 1 diabetes (T1D) in children involves autoimmune destruction of pancreatic ß- cells, leading to insulin deficiency. Verapamil is an L-type calcium channel blocker that has been used for decades to treat hypertension and certain cardiac conditions. Recent research has revealed its potential as a ß- cell-protective agent. Hence this study will evaluate the effect of once-daily oral verapamil on pancreatic ß- cell reserve , glycemic metrics and daily insulin requirements in children and adolescents with T1D.

Official title: Efficay and Safety of Oral Verapamil on Glycemic Metrics and ß-cell Reserve Among Newly Diagnosed Children and Adolescents With Type 1 Diabetes

Key Details

Gender

All

Age Range

10 Years - 18 Years

Study Type

INTERVENTIONAL

Enrollment

70

Start Date

2026-08-20

Completion Date

2027-03-20

Last Updated

2026-09-04

Healthy Volunteers

No

Interventions

DRUG

Verapamil oral

active comparator

DRUG

Placebo

placebo comparator

Locations (1)

Ain Shams University

Cairo, Egypt